Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae

References

• World Health Organization. Global action plan on antimicrobial resistance. Available from: http://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1;2015. Accessed November 30, 2021.
   Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–1798. doi:10.3201/eid1710.11065522000347
   PubMed Web of Science ®Google Scholar
• Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA. 2020;6:FSO438. doi:10.2144/fsoa-2019-009832140243
   PubMed Web of Science ®Google Scholar
• Chiu SK, Chan MC, Huang LY, Lin YT, Yeh KM. Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: clinical characteristics and expression levels of efflux pump genes. PLoS One. 2017;12:e0175140. doi:10.1371/journal.pone.017514028388651
   PubMed Web of Science ®Google Scholar
• Cristina ML, Alicino C, Sartini M, et al. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health. 2018;11(2):171–177. doi:10.1016/j.jiph.2017.06.00328668656
   PubMed Web of Science ®Google Scholar
• Spagnolo AM, Orlando P, Panatto D, Perdelli F, Cristina ML. An overview of carbapenem-resistant Klebsiella pneumoniae: epidemiology and control measures. Rev Med Microbiol. 2014;25:7–14. doi:10.1097/MRM.0b013e328365c51e
   Google Scholar
• Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19:601–610. doi:10.1016/S1473-3099(18)30792-831047852
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas AKZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20:1170–1175. doi:10.3201/eid2007.12100424959688
   PubMed Web of Science ®Google Scholar
• Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, et al. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. J Antimicrob Chemother. 2021;76(1):220–225. doi:10.1093/jac/dkaa39733038895
   PubMed Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, Liu Q, Li B. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31. doi:10.1016/j.jiph.2018.08.00230145151
   PubMed Web of Science ®Google Scholar
• Cristina ML, Sartini M, Ottria G, et al. Epidemiology and biomolecular characterization of carbapenem-resistant Klebsiella pneumoniae in an Italian hospital. J Prev Med Hyg. 2016;57(3):E149–E156.27980379
   PubMedGoogle Scholar
• Bartsch SM, Huang SS, McKinnell JA, et al. The economic value of the centers for disease control and prevention carbapenem-resistant Enterobacteriaceae toolkit. Infect Control Hosp Epidemiol. 2018;39(5):516–524. doi:10.1017/ice.2018.4929552995
   PubMed Web of Science ®Google Scholar
• Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2017;23:48.e49–48.e16. doi:10.1016/j.cmi.2016.09.003
   Web of Science ®Google Scholar
• Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of disease studies using disability-adjusted life years. Popul Health Metr. 2012;10:21. doi:10.1186/1478-7954-10-2123113929
   PubMed Web of Science ®Google Scholar
• Lamberti LM, Fischer Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. BMC Public Health. 2012;12:276. doi:10.1186/1471-2458-12-27622480268
   PubMed Web of Science ®Google Scholar
• Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129–2143. doi:10.1016/S0140-6736(12)61680-823245605
   PubMed Web of Science ®Google Scholar
• Jia H, Li W, Hou T, et al. The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China. Biomed Res Int. 2019;2019:7634528. doi:10.1155/2019/763452830949509
   PubMed Web of Science ®Google Scholar
• Friedrich AW. Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go. Wien Med Wochenschr. 2019;169(Suppl 1):25–30. doi:10.1007/s10354-018-0676-5
   Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing——Twenty-Ninth Edition: M100. CLSI; 2019.
   Google Scholar
• Bank of China. Available from: https://srh.bankofchina.com/search/whpj/search_cn.jsp. Accessed November 30, 2021.
   Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829. doi:10.1097/00003246-198510000-000093928249
   PubMed Web of Science ®Google Scholar
• Rhee JY, Kwon KT, Ki HK, Sang YS, Song JH. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009;31:146–150. doi:10.1097/SHK.0b013e318182f98f18636041
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• World Health Organization. Health statistics and information systems, metrics: disability-adjusted life year (DALY). Available from: https://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/. Accessed November 30, 2021.
   Google Scholar
• Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–331. doi:10.1093/heapol/16.3.32611527874
   PubMed Web of Science ®Google Scholar
• World Health Organization. Disability weights, discounting and age weighting of DALYs. Available from: https://www.who.int/healthinfo/global_burden_disease/daly_disability_weight/en/. Accessed November 30, 2021.
   Google Scholar
• Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3:e712–e723. doi:10.1016/S2214-109X(15)00069-826475018
   PubMed Web of Science ®Google Scholar
• Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.27733282
   PubMed Web of Science ®Google Scholar
• WHO methods and data sources for global burden of disease estimates 2000-2015. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf?ua=1. Accessed November 30, 2021.
   Google Scholar
• Barnum H. Evaluating healthy days of life gained from health projects. Soc Sci Med. 1987;24:833–841. doi:10.1016/0277-9536(87)90184-53112960
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. Available from: http://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed November 30, 2021.
   Google Scholar
• Kaye KS, Pogue JM. Infections Caused by Resistant Gram-Negative Bacteria: epidemiology and Management. Pharmacotherapy. 2015;35:949–962. doi:10.1002/phar.163626497481
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62:e01882–17. doi:10.1128/AAC.01882-1729203488
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707. doi:10.1128/CMR.05035-1123034326
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328. doi:10.1128/AAC.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Huang W, Qiao F, Zhang Y, et al. In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;67:S225–S230. doi:10.1093/cid/ciy64230423052
   PubMed Web of Science ®Google Scholar
• Meng X, Liu S, Duan J, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis. 2017;17:82. doi:10.1186/s12879-016-2176-928095785
   PubMed Web of Science ®Google Scholar
• Vargas-Alzate CA, Higuita-Gutiérrez LF, López-López L, Gallet AVC, Quicenoet JNJ. High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region. Int J Antimicrob Agents. 2018;51:601–607. doi:10.1016/j.ijantimicag.2017.12.01229277527
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan M, Shorr AF. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study. Antimicrob Resist Infect Control. 2017;6:124. doi:10.1186/s13756-017-0286-929225798
   PubMed Web of Science ®Google Scholar
• Muller A, Reutzel TJ. Willingness to pay for reduction in fatality risk: an exploratory survey. Am J Public Health. 1984;74:808–812. doi:10.2105/AJPH.74.8.8086430109
   PubMed Web of Science ®Google Scholar